Some studies have found that colorectal cancer patients with PIK3CA gene mutations have poor efficacy when using anti-EGFR monoclonal antibodies, with significantly shortened progression-free survival and overall survival (Wang et al., 2022; Tan et al., 2022). The gene discussed is PIK3CA; the disease is colorectal cancer.